Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Mahnoush Bahjat
The NEDD8-activating Enzyme Inhibitor MLN4924 Induces DNA Damage in Ph+ Leukemia and Sensitizes for ABL Kinase Inhibitors
Cell Cycle
Medicine
Developmental Biology
Cell Biology
Molecular Biology
DNA Polymerase Β Prevents AID-instigated Mutagenic Non-Canonical Mismatch DNA Repair
Related publications
The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth
Cancer Research
Cancer Research
Oncology
Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924
Cancer Cell
Cancer Research
Oncology
Cell Biology
Pevonedistat, a Nedd8-Activating Enzyme Inhibitor, Sensitizes Neoplastic B-Cells to Death Receptor-Mediated Apoptosis
Oncotarget
Oncology
Neural Precursor Cell Expressed, Developmentally Downregulated 8-Activating Enzyme Inhibitor MLN4924 Sensitizes Colorectal Cancer Cells to Oxaliplatin by Inducing DNA Damage, G2 Cell Cycle Arrest and Apoptosis
Molecular Medicine Reports
Oncology
Genetics
Molecular Biology
Biochemistry
Cancer Research
Molecular Medicine
PARP Inhibitor Re‑sensitizes Adriamycin Resistant Leukemia Cells Through DNA Damage and Apoptosis
Molecular Medicine Reports
Oncology
Genetics
Molecular Biology
Biochemistry
Cancer Research
Molecular Medicine
Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia
Haematologica
Hematology
Expanded Safety Analysis of Pevonedistat, a First-In-Class NEDD8-activating Enzyme Inhibitor, in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Blood Cancer Journal
Oncology
Hematology
The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR/ABL-Expressing Cells to Tyrosine Kinase Inhibitors
International Journal of Molecular Sciences
Organic Chemistry
Molecular Biology
Theoretical Chemistry
Inorganic Chemistry
Computer Science Applications
Spectroscopy
Medicine
Catalysis
Physical
Current Status of ABL Tyrosine Kinase Inhibitors Stop Studies for Chronic Myeloid Leukemia
Stem Cell Investigation
